Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Director Sells 3,504 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) Director Robert Chess sold 3,504 shares of the company's stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $51.85, for a total value of $181,682.40. Following the sale, the director now owns 21,641 shares in the company, valued at approximately $1,122,085.85. This represents a 13.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Robert Chess also recently made the following trade(s):

• On Monday, November 11th, Robert Chess sold 3,600 shares of Twist Bioscience stock. The shares were sold at an average price of $47.26, for a total transaction of $170,136.00.

Twist Bioscience Stock Down 2.0 %

Shares of NASDAQ TWST traded down $0.94 during midday trading on Monday, reaching $47.23. The company had a trading volume of 457,416 shares, compared to its average volume of 937,404. The stock has a market cap of $2.80 billion, a PE ratio of -13.12 and a beta of 1.82. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The firm's fifty day moving average price is $45.61 and its 200-day moving average price is $46.65.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Leerink Partners increased their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a research report on Thursday, October 17th. Barclays lowered their price target on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a report on Tuesday, November 19th. Evercore ISI upped their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Wolfe Research started coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 target price for the company. Finally, TD Cowen reissued a "buy" rating and issued a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $51.90.

Institutional Trading of Twist Bioscience

A number of institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. increased its position in shares of Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company's stock valued at $9,301,000 after acquiring an additional 82,953 shares during the period. Oddo BHF Asset Management Sas bought a new stake in shares of Twist Bioscience in the third quarter worth about $3,302,000. Beaird Harris Wealth Management LLC purchased a new position in Twist Bioscience during the 3rd quarter valued at about $95,000. Franklin Resources Inc. raised its position in Twist Bioscience by 3.4% during the 3rd quarter. Franklin Resources Inc. now owns 252,064 shares of the company's stock valued at $11,756,000 after purchasing an additional 8,308 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Twist Bioscience in the 3rd quarter worth approximately $34,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.